Weiss Ratings Reiterates "Sell (E+)" Rating for Telomir Pharmaceuticals (NASDAQ:TELO)

Key Points

• Weiss Ratings has restated its "Sell (E+)" rating for Telomir Pharmaceuticals (NASDAQ:TELO), indicating continued negative sentiment towards the company's stock performance.
• The company's stock opened at $1.65, with a market cap of $53.26 million and a 52-week trading range of $1.12 to $7.08, highlighting significant volatility.
• Telomir Pharmaceuticals reported a loss of ($0.17) earnings per share for the last quarter, missing analysts' expectations, with projected EPS of -0.4 for the current fiscal year.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report)'s stock had its "sell (e+)" rating restated by equities research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Telomir Pharmaceuticals Stock Performance

NASDAQ:TELO opened at $1.65 on Wednesday. The stock has a fifty day moving average price of $1.47 and a 200-day moving average price of $1.98. The company has a market cap of $53.26 million, a price-to-earnings ratio of -3.06 and a beta of -0.60. Telomir Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $7.08.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.09). Research analysts predict that Telomir Pharmaceuticals will post -0.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Telomir Pharmaceuticals by 283.9% in the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company's stock worth $61,000 after purchasing an additional 10,880 shares in the last quarter. Nuveen LLC acquired a new position in Telomir Pharmaceuticals in the 1st quarter worth about $81,000. Qube Research & Technologies Ltd acquired a new position in Telomir Pharmaceuticals in the 2nd quarter worth about $33,000. HighTower Advisors LLC acquired a new position in Telomir Pharmaceuticals in the 1st quarter worth about $139,000. Finally, Jane Street Group LLC acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at about $62,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.